|
|
Blood, 15 October 2006, Vol. 108, No. 8, pp. 2811-2813.
Prepublished online as a Blood First Edition Paper on June 29, 2006; DOI 10.1182/blood-2006-04-017400.
 Previous Article | Next Article 
Submitted April 19, 2006
Accepted June 3, 2006
Myelodysplastic syndromes and acute leukemia developing
after imatinib mesylate therapy for chronic myeloid leukemia
Craig Kovitz, Hagop Kantarjian, Guillermo Garcia-Manero, Lynne V Abruzzo, and Jorge Cortes*
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
* Corresponding author; email: jcortes{at}mdanderson.org.
During therapy with imatinib, some patients with chronic myeloid leukemia (CML) develop chromosomal abnormalities in Ph-negative cells. These are frequently transient and their clinical consequence is unclear. Although some reports have suggested these abnormalities might be associated with secondary myelodysplastic syndrome (MDS), the diagnosis has not always been established using standard criteria. We report 3 cases of patients treated with imatinib for CML who were subsequently found to have chromosomal abnormalities in Ph-negative cells. One of them developed acute myelogenous leukemia (AML) and the other two developed high risk MDS which rapidly transformed to AML. These cases were identified in a total study group of 1701 patients. Although rare, these findings highlight the need for close monitoring of patients with CML treated with imatinib.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Quintas-Cardama and J. Cortes
Molecular biology of bcr-abl1-positive chronic myeloid leukemia
Blood,
February 19, 2009;
113(8):
1619 - 1630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Fabarius, M. Giehl, B. Rebacz, A. Kramer, O. Frank, C. Haferlach, P. Duesberg, R. Hehlmann, W. Seifarth, and A. Hochhaus
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib
Haematologica,
August 1, 2008;
93(8):
1145 - 1154.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Bedell, S. J. Forman, K. Gaal, V. Pullarkat, L. M. Weiss, and M. L. Slovak
Successful Application of a Direct Detection Slide-Based Sequential Phenotype/Genotype Assay Using Archived Bone Marrow Smears and Paraffin Embedded Tissue Sections
J. Mol. Diagn.,
November 1, 2007;
9(5):
589 - 597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, H. M. Kantarjian, L. V. Abruzzo, S. O'Brien, G. Garcia-Manero, S. Verstovsek, J. Shan, M. B. Rios, and J. Cortes
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Blood,
October 15, 2007;
110(8):
2991 - 2995.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Goldman
How I treat chronic myeloid leukemia in the imatinib era
Blood,
October 15, 2007;
110(8):
2828 - 2837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Schiffer
BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
N. Engl. J. Med.,
July 19, 2007;
357(3):
258 - 265.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Fabarius, C. Haferlach, M. C. Muller, P. Erben, T. Lahaye, M. Giehl, O. Frank, W. Seifarth, R. Hehlmann, and A. Hochhaus
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure
Haematologica,
June 1, 2007;
92(6):
834 - 837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Branford
Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice
Hematology,
January 1, 2007;
2007(1):
376 - 383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
